Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care.
Curr Opin Cardiol
; 35(5): 589-601, 2020 09.
Article
em En
| MEDLINE
| ID: mdl-32694262
ABSTRACT
PURPOSE OF REVIEW The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS:
Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes.SUMMARY:
Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Diabetes Mellitus Tipo 2
/
Inibidores do Transportador 2 de Sódio-Glicose
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article